Abstracts tagged "Abatacept"

Abstract Number: 1536 • 2014 ACR/ARHP Annual Meeting
Comparing Abatacept to Adalimumab, Etanercept and Infliximab As First Line Agents in Patients with Rheumatoid Arthritis. Experience from the Rhumadata® Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Isabelle Fortin³, Boulos Haraoui¹, Jean Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard⁴, Diane Sauvageau¹, Edith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁴Rhumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada
Background/Purpose: The order of use of biologic agents is still a question for debate. Phase III trial data in MTX-IR patients show comparable efficacy results…
Abstract Number: 465 • 2013 ACR/ARHP Annual Meeting
Higher Titer Of Anti-Citrullinated Protein Antibodies In Biologic-Naïve Rheumatoid Arthritis Patients Are Candidate Biomarkers To Predict Sensitivity Leading To Clinical Remission With Abatacept; Data From The Abroad Study
Takao Fujii¹, Masahiro Sekiguchi², Kiyoshi Matsui², Masayasu Kitano², Motomu Hashimoto³, Koichiro Ohmura⁴, Aihiro Yamamoto⁵, Hideko Nakahara⁶, Keiji Maeda⁷, Akira Yokota⁸, Kenji Miki⁹, Naoki Shimmyo¹⁰, Takanori Kuroiwa¹¹, Kosaku Murakami¹², Yoshio Ozaki¹³, Kenshi Higami¹⁴, Ichiro Yoshii¹⁵, Yuji Nozaki¹⁶, Takashi Ikawa¹⁷, Satoshi Morita¹⁸, Yutaka Kawahito⁵, Norihiro Nishimoto¹⁹, Tsuneyo Mimori⁴ and Hajime Sano², ¹Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya-city, Japan, ³The Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ⁶Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ⁷Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ⁸Yokota Clinic for Rheumatology, Osaka, Japan, ⁹Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan, ¹⁰Kashiba Asahigaoka Hospital, Kashiba, Japan, ¹¹Department of Rheumatology, Yukioka Hospital, Osaka, Japan, ¹²Dept of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ¹³Kansai Medical University Hirakata Hospital, Hirakata, Japan, ¹⁴Department of Rheumatology, Higami Hospital, Nara, Japan, ¹⁵Department of Orthopaedic Surgery, Yoshii Hospital, Shimanto, Japan, ¹⁶Kinki University Faculty of Medicine, Sayama, Japan, ¹⁷Osaka Rehabilitation Hospital, Hannan, Japan, ¹⁸Graduate School of Medicine & Medical Center, Department of Biostatistics and Epidemiology, Yokohama City University, Kanagawa, Japan, ¹⁹Osaka Rheumatology Clinic, Osaka, Japan
Background/Purpose: Biomarkers to predict each rheumatoid arthritis (RA) patient’s sensitivity for biologic disease modifying anti-rheumatic diseases, especially for the only T cell modulator abatacept (ABT),…
Abstract Number: 2910 • 2013 ACR/ARHP Annual Meeting
Differences In Abatacept Use In Rheumatoid Arthritis Patients Across Europe: A Pan-European Database Analysis Of Abatacept In European RA Registries
David Neto¹, Axel Finckh², Florenzo Iannone³, Estíbaliz Loza⁴, Elisabeth Lie⁵, Piet L.C. Van Riel⁶, Merete L. Hetland⁷, Karel Pavelka⁸, Jacques-Eric Gottenberg⁹, Xavier Mariette¹⁰ and Carl Turesson¹¹, ¹University of Geneva, Geneva, Switzerland, ²Rheumatology, Geneva University Hospital, Geneva, Switzerland, ³D.I.M.I.M.P, Rheumatology Unit - University of Bari, Bari, Italy, ⁴Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ⁵Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁷Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ⁸Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, ⁹Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ¹⁰Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ¹¹Department of Rheumatology, Skåne University Hospital, Malmö, Sweden
Background/Purpose: Several European registries have pooled data of patients (pts) who received Abatacept (ABA) for rheumatoid arthritis (RA) to acquire new knowledge about performance of…
Abstract Number: 468 • 2013 ACR/ARHP Annual Meeting
The Differential Role Of T Helper Cells In The Pathogenesis and Responsiveness To Abatacept Therapy In Rheumatoid Arthritis
Shunsuke Fukuyo¹, Shingo Nakayamada², Kunihiro Yamaoka¹, Satoshi Kubo¹, Shigeru Iwata³, Kazuyoshi Saito¹ and Yoshiya Tanaka¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, Kitakyushu, Japan
Background/Purpose: Abatacept (ABT) works through a different mechanism of action from TNF inhibitors in the treatment of rheumatoid arthritis (RA). ABT decreases T cell responses…
Abstract Number: 2349 • 2013 ACR/ARHP Annual Meeting
Abatacept and Anti-Tumor Necrosis Factor Monoclonal Antibodies: Efficacy and Safety Comparisons
M Schiff¹, Maxime Dougados², Roy Fleischmann³, J Fay⁴ and M Maldonado⁴, ¹University of Colorado, Denver, CO, ²Rheumatology, Hopital Cochin, Descartes University, Paris, France, ³University of Texas Southwestern Medical Center, Dallas, TX, ⁴Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: A paucity of clinical trial data exists comparing the efficacy and safety of biologic therapies for RA. This study evaluated remission rates and safety…
Abstract Number: 476 • 2013 ACR/ARHP Annual Meeting
Two-Year Results From The Ample Trial: Low Disease Activity and Association Between Remission and Changes In Physical Function and Radiographic Outcomes With Subcutaneous Abatacept Or Adalimumab
Roy Fleischmann¹, M Schiff², M E Weinblatt³, M Maldonado⁴, E Massarotti⁵ and Y Yazici⁶, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²University of Colorado, Denver, CO, ³Brigham & Women's Hospital, Boston, MA, ⁴Bristol-Myers Squibb, Princeton, NJ, ⁵Brigham and Women's Hospital, Boston, MA, ⁶New York University Hospital for Joint Diseases, New York, NY
Background/Purpose: Remission and low disease activity (LDA) are now more achievable goals in RA. Year 1 data from the head-to-head AMPLE (Abatacept vs Adalimumab Comparison…
Abstract Number: 2326 • 2013 ACR/ARHP Annual Meeting
Head-To-Head Comparison Of Subcutaneous Abatacept Versus Adalimumab On Background Methotrexate In RA: Blinded Two Year Results From The Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjectswith Background Methotrexate) study
Michael E. Weinblatt¹, Michael H Schiff², Robert Valente³, Désirée M. van der Heijde⁴, Gustavo Citera⁵, Ayanbola Elegbe⁶, Michael A Maldonado⁶ and Roy Fleischmann⁷, ¹Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA, ²University of Colorado, Denver, CO, ³Arthritis Center of Nebraska, Lincoln, NE, ⁴Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) is the first 2 year, active comparator study in RA patients utilizing…
Abstract Number: 454 • 2013 ACR/ARHP Annual Meeting
Antibody Response To Pneumococcal and Influenza Vaccination In Patients With Rheumatoid Arthritis Receiving Subcutaneous Abatacept
MC Genovese¹, Clifton O. Bingham III², S Cohen³, Leonard H. Calabrese⁴, JR Curtis⁵, A Block⁶, J Fay⁶, S Kelly⁷, A Luo⁶, D Wong⁶ and R Alten⁸, ¹Stanford University, Palo Alto, CA, ²Johns Hopkins University, Baltimore, MD, ³Metroplex Clinical Research Center, Dallas, TX, ⁴Cleveland Clinic Foundation, Cleveland, OH, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷Bristol-Myers Squibb, Plainsboro, NJ, ⁸Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany
Background/Purpose: Previous small studies have suggested that responses to some immunizations may be attenuated by intravenous abatacept but remain clinically meaningful.1,2 We investigated the magnitude…
Abstract Number: 1457 • 2013 ACR/ARHP Annual Meeting
Inhibitory Effect Of Abatacept On Joint Damage In Rheumatoid Arthritis Patients With Or Without Concomitant Methotrexate: A Retrospective Multicenter Analysis Of 12 Months Of Abatacept Treatment In Routine Clinical Practice
Isao Matsushita¹, Hiraku Motomura¹, Eiko Seki¹ and Tomoatsu Kimura², ¹Department of Orthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan, ²Department of rthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan
Background/Purpose: Abatacept is approved for use with or without methotrexate (MTX). The purpose of this study was to clarify the inhibitory effect of abatacept on…
Abstract Number: 424 • 2013 ACR/ARHP Annual Meeting
2-Year Results From The Ample (Abatacept versus Adalimumab Comparison in Biologic-Naïve RA Patients with Background Methotrexate) Trial: Changes In Patient-Reported Outcomes In Response To Subcutaneous Abatacept Or Adalimumab In Rheumatoid Arthritis
Roy Fleischmann¹, ME Weinblatt², M Schiff³, D Khanna⁴, MA Maldonado⁵, A Nadkarni⁶ and Daniel Furst⁷, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ³University of Colorado, Denver, CO, ⁴University of Michigan, Ann Arbor, MI, ⁵Bristol-Myers Squibb, Princeton, NJ, ⁶Bristol-Myers Squibb, Plainsboro, NJ, ⁷University of California at Los Angeles, Los Angeles, CA
Background/Purpose: RA is a debilitating disease that can impact health-related quality of life (HRQoL) through impairment of activity, loss of independence and reduced work productivity.…
Abstract Number: 1465 • 2013 ACR/ARHP Annual Meeting
Adherence To The Recommended Dosing Regimen Of Abatacept In The Real-World Setting In The Action Study: Is There a Dose-Creep In Overweight Patients?
H Nüßlein¹, R Alten², M Galeazzi³, H M Lorenz⁴, D Boumpas⁵, M T Nurmohamed⁶, W G Bensen⁷, Gerd Burmester⁸, H-H Peter⁹, F Rainer¹⁰, K Pavelka¹¹, M Chartier¹², C Poncet¹³, C Rauch¹⁴ and M Le Bars¹⁵, ¹University Erlangen, Nürnberg, Germany, ²Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ³University of Siena, Siena, Italy, ⁴University Hospital Heidelberg, Heidelberg, Germany, ⁵Panepistimio Kritis, Rethymnon, Greece, ⁶VU University Medical Center/Jan van Breeman Research Institute, Amsterdam, Netherlands, ⁷St. Joseph's Hospital/McMaster University, Hamilton, ON, Canada, ⁸Charité-Universitätsmedizin, Berlin, Germany, ⁹University of Freiburg, Freiburg, Germany, ¹⁰Hospital Barmherzige Brueder, Graz, Austria, ¹¹Institute of Rheumatology, Prague, Czech Republic, ¹²Chiltern International, Neuilly, France, ¹³Docs International, Nanterre, France, ¹⁴Bristol-Myers Squibb, Munich, Germany, ¹⁵Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: Reduced efficacy for achieving DAS28 30 kg/m2,1 which in theory could induce dose increases to maintain efficacy. Here we explore adherence to abatacept over…
Abstract Number: 1442 • 2013 ACR/ARHP Annual Meeting
Three-Year Drug Survival and Effectiveness Of Abatacept and Tocilizumab In Patients with Rheumatoid Arthritis Treated In Routine Care. Results From The Nationwide Danish Danbio Registry
HCB Leffers^1,2, Mikkel Østergaard³, Bente Glintborg⁴, Niels Steen Krogh⁵, Ulrik Tarp⁶, Tove Lorenzen⁷, Annette Hansen⁸, Lene Dreyer⁹ and Merete L. Hetland³, ¹DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Glostrup, Denmark, ²Department of Rheumatology, Frederiksberg Hospital, Frderiksberg, Denmark, ³Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, ⁵ZiteLab ApS, Copenhagen, Denmark, ⁶Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁷Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, ⁸Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, ⁹Internal Medicine - Rheumatology Section, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark
Background/Purpose: Treatment with abatacept and tocilizumab has been shown to be efficacious in rheumatoid arthritis (RA) patients refractory to tumor necrosis factor inhibitor (TNFi). However,…
Abstract Number: 1448 • 2013 ACR/ARHP Annual Meeting
Drug Retention Rates Of Biologic Monotherapies For Patients With Rheumatoid Arthritis In Daily Clinical Practice; Using Multicenter Registry In Japan
Hiroyuki Matsubara¹, Toshihisa Kojima², Masatoshi Hayashi³ and Naoki Ishiguro⁴, ¹Rheumatology, Handa Municipal Hospital, Handa, Japan, ²Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, ³Departments of Orthopedic surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ⁴Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: In general, drug retention rate reflects the effectiveness and tolerability of the drug. In Japan, six biological agents have been approved for the treatment…
Abstract Number: 1455 • 2013 ACR/ARHP Annual Meeting
Comparison Of Serum Matrix Metalloproteinase-3 Levels In Rheumatoid Arthritis After Treatment With Adalimumub Or Abatacept For 24 Weeks
Yosuke Hattori¹, Atsushi Kaneko¹, Daihei Kida², Hisato Ishikawa³, Toshihisa Kojima⁴ and Naoki Ishiguro⁵, ¹Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan, ²Department of Rheumatology and Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, ³Nagoya Medical Center, nagano, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, ⁵Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose : MMP-3 is an enzyme produced by synoviocytes, and is a marker of synovitis that gives a more direct indication of actual joint destruction…
Abstract Number: 1385 • 2013 ACR/ARHP Annual Meeting
A Study Of Natural Killer Cell Subfractions In Abatacept Therapy For Rheumatoid Arthritis
Masao Sato¹, Masao Takemura², Ryuki Shinohe¹, Yasuko Yamamoto³ and Kuniaki Saito³, ¹Orthopaedic Surgery, Gifu University, Gifu, Japan, ²Informative Clinical Medicine, Gifu University, Gifu, Japan, ³Human Health Science, Kyoto University, Kyoto, Japan
Background/Purpose: Inflammatory cytokines and cell-mediated immunity function of mainly lymphocytes are complicatedly involved in disease onset of rheumatoid arthritis (RA). Recently, together with biologicals such…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].